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Elevated	 levels	of	 circulating	endothelial	 cells	 (CECs)	and	 low	 levels	of	endothelial	
progenitor	cells	 (EPCs)	have	been	described	 in	different	cardiovascular	conditions,	
suggesting	their	potential	use	as	diagnostic	biomarkers	for	endothelial	dysfunction.	
Compared	 to	 typical	peripheral	blood	 leukocyte	subsets,	CECs	and	EPCs	occur	at	






ple	 storage	conditions	were	optimized	as	prerequisite	 for	 clinical	use.	 In	a	 second	
phase,	CECs	and	EPCs	were	analyzed	 in	heart	 failure	with	preserved	 (HFpEF)	and	
reduced	(HFrEF)	ejection	fraction,	in	arterial	hypertension	(aHT),	and	in	diabetic	ne-
phropathy	(DN)	in	comparison	to	age-	matched	healthy	controls.
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1  | INTRODUCTION
Cardiovascular	 diseases	 are	 still	 the	major	 cause	 of	 death	world-
wide.1	 The	 endothelium	 does	 not	 only	 form	 a	 physical	 barrier	















microscopically	 described	 already	 decades	 ago12 and their identity 
was	confirmed	by	specific	staining	with	endothelium-	specific	antibod-
ies.13,14	The	origin	of	CECs,	their	detection	methods,	and	the	associ-







Mature	 CECs	 have	 to	 be	 discriminated	 from	 circulating	 endo-
thelial	progenitor	cells	 (EPCs).	The	progenitor	cells	are	responsible	
for	 repair	 and	 renewing	of	damaged	endothelium	because	mature	
endothelial	cells	are	believed	to	have	only	limited	regenerative	po-

























centrations.	 The	 experimental	 procedure	 was	 complemented	 with	
the	use	of	transfix	tubes	in	order	to	allow	delayed	analysis	in	multi-	




2  | MATERIAL AND METHODS
2.1 | Subjects and sample collection









Blood	 samples	 from	 patients	 and	 controls	 were	 drawn	 in	
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CD31+,	 and	 CD146+.25	 Microvascular	 CECs	 (mvCECs)	 were	 identi-








respectively)	 were	 incubated	 with	 FcR	 blocking	 Reagent	 (Miltenyi,	
Bergisch	 Gladbach,	 Germany)	 for	 15	minutes	 at	 4°C,	 and	 then	with	
the	respective	antibody	mixtures	for	40	minutes	at	4°C.	After	red	cell	
lysis	with	High-	Yield	Lyse	 (Life	Technologies,	Carlsbad,	CA,	USA)	 for	





















2.3 | Cell culture and cell spiking

















To	 test	 the	 sensitivity	 of	 CEC	 quantification,	 blood	 samples	 from	
healthy	donors	were	 spiked	with	HUVECs	or	HMVECs	at	 increas-
ing	 concentrations	 in	 range	100-	10	000	 cells	mL−1 as described in 
the	previous	section.	The	recovery	rate	of	endothelial	cells	in	spiked	
whole	 blood	 samples	was	 calculated	 as:	 (detected	ECs	 concentra-
tion)/(spiked	 EC	 concentration)	×	100.	 Assay	 precision	 was	 deter-

























3.1 | Detection of CECs and EPCs by flow cytometry
Circulating	endothelial	cells	were	detected	by	five-	color	flow	cytom-





and	doublets	in	the	FSC-	A/FSC-	H	dot-	plot,	DNA+ cells were identi-
fied	on	the	basis	of	the	positivity	for	Syto16,	and	then	DNA+	CD45low 
CD31+	 cells	 were	 subgated.	 Finally,	 CECs	 were	 identified	 subgat-
ing	from	this	subpopulation	the	CD31+	CD146+ cells. Microvascular 
CECs	were	then	identified	as	CD36+	CECs.	This	gating	strategy	was	
set	 and	 validated	 using	 blood	 samples	 spiked	 with	 HUVECs	 and	
HMVECs,	as	model	for	respectively	macrovascular	and	microvascular	
cells	 (Figure	1B).	 In	particular,	 the	gate	 for	CD36	positivity	was	set	













identified.	 EPC	 identity	was	 further	 confirmed	analyzing	CD31	ex-
pression.	Positive/negative	boundaries	were	set	through	FMO	con-
trols	using	matched	isotype	controls	(Figure	S2).
3.2 | Detection recovery of CECs in whole 
blood samples






percentages	 of	 recovered	 HUVECs	 and	 HMVECs	 ranged	 between	
83%	and	115%	for	the	three	levels	of	spiking	concentrations.	The	level	
of	CD36	staining	on	L-	HMVEC	remained	stable	at	the	different	spiked	
cell	 concentrations	 tested;	 the	 percentage	 of	 CD36+	 cells	 at	 100,	































Li-	Heparin,	 respectively.	Moreover,	 the	 inter-	assay	 variation	 be-
tween	 the	 analyses	 at	 0	hour,	 24	hours,	 48	hours,	 and	 72	hours	
was	much	 lower	 in	 Transfix	 (6.7%)	 than	 in	 EDTA	 and	 Li-	heparin	
tubes	 (17.7%	and	10.5%,	 respectively).	The	 levels	of	CECs	quan-









vascular	 cells.	 The	 intra-	assay	 and	 inter-	assay	 variations	 for	 the	
detection	of	both	spiked	endothelial	cells	and	EPCs	(Table	1)	were	
lower	 than	 20%,	 proving	 the	 reproducibility	 of	 the	 developed	
quantification	method.
3.4 | CEC and EPC levels in clinical samples
Circulating	endothelial	cells	and	EPCs	were	quantified	 in	patients	
with	DN,	HFpEF,	HFrEF,	 aHT,	 and	 age	matched	healthy	 controls.	
Patient	characteristics	are	shown	in	Table	S1.	Blood	samples	were	
collected	 in	 Transfix-	tubes	 and	 analyzed	 between	 1	 and	 3	days	
after	 collection.	 CEC	 counts	 were	 significantly	 elevated	 in	 DN	
(16.7	 [9.7-	28.1]	 cells	 mL−1,	 P < 0.05)	 and	 HFpEF	 (23.0	 [8.1-	31.7]	
cells	mL−1,	P < 0.05)	in	comparison	to	healthy	individuals	(5.5	[4-	7.3]	





(27.5%	 [14.9-	51.8]),	 but	 not	 in	 DN	 (59.4%	 [39.7-	70.4])	 and	HFrEF	
(52.2%	[22.7-	70.3]).
Endothelial	 progenitor	 cell	 levels	 were	 similar	 between	 
the	 different	 groups	 analyzed,	 with	 values	 of	 831	 (556.8-	1138.0)	
cells	mL−1	 in	healthy	volunteers,	661.0	 (466.0-	1267.0)	cells	mL−1 in 
DN,	 716.0	 (527.0-	904.0)	 cells	 mL−1	 in	 HFpEF,	 853.0	 (514.5-	1889)	
cells	mL−1	in	HFrEF,	and	801.5	(477.5-	1186)	cells	mL−1 in aHT.
3.5 | Diagnostic values of CEC count for 
DN and HFpEF
Comparing	 the	 cohorts	of	DN,	HFpEF,	HFrEF,	 and	aHT	with	 the	




sensitivity	 was	 of	 70.4%	 (49.8%-	86.3%)	 and	 the	 PPV	 was	 95%	
(75.1%-	99.9%).	 The	 sensitivity	 for	 aHT	 detection	 was	 of	 66.7%	
(44.7%-	84.4%)	and	the	PPV	of	94.1%	(71.3%-	99.9%);	the	sensitiv-
ity	for	HFrEF	was	52%	(31.3%-	72.2%),	and	the	PPV	92.8%	(66.1%-	
99.8%).	 The	CEC	 counts	 showed	 a	 diagnostic	 specificity	 of	 90%	
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except	 for	HFrEF	where	NPV	was	 of	 42.9%	 (21.8%-	65.9%).	 The	










our	 results	 are	 comparable	 to	 those	 obtained	 by	 other	 detection	
techniques	 like	 IHC,31	 IMS,20,32	 and	CellSearch33	 (3.8	 [0.75-	16.75]	
cells	mL−1).	 In	contrast	very	high	CEC	counts	(140	±	171	cells	mL−1)	
were	 detected	 by	Mancuso	 et	al.,25	which	 used	 a	 CECs	 definition	
similar	to	our	(CECs:	Syto16+CD45−CD31+CD146+).	But,	however,	as	
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In	comparison	to	the	already	established	methods	for	CEC	and	


















mia31	 and	with	 pulmonary	 hypertension.32	 Although	 the	distinc-
tion	between	micro-	and	macrovascular	cells	assessed	on	the	basis	




Elevated	 levels	of	CECs	 in	heart	 failure	have	been	described37 












dothelial	 dysfunction	 as	 underlying	 disease	 mechanism	 (reviewed	
elsewhere40):	Endothelial	dysfunction	 is	associated	with	HFpEF	as	
shown	by	Akiyama	et	al.41	and	has	prognostic	value.42 Mohammed 
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fibrosis,	 and	 imbalance	of	 coronary	microvascular	destruction	and	
regeneration	are	associated	with	HFpEF.






and	 on	 expression	 of	 specific	 isoforms	 of	 Titin	 and	 their	 phos-
phorylation	status	on	the	other	hand.	The	common	denominator	
of	 these	changes	 is	 the	endometrial	dysfunction,	which	 leads	 to	
lower	levels	of	nitric	oxide	signaling	in	the	blood	vessels	and	also	
in	the	cardiomyocytes.	The	resulting	lower	cGMP	concentrations	
increase	 calcium	 sensitivity	 and	 therefore	 prevent	 diastolic	 re-
laxation	and	lower	PKG	activity,	which	is	required	for	Titin	phos-









With	 the	 improved	 sensitivity,	 our	 validated	 assay	 opens	 the	
perspective	 to	a	 future	use	as	additional	diagnostic	 tool	 for	early	
detection	 of	 cardiovascular	 diseases	 associated	 with	 endothelial	
damage.





individuals were similar to those described by Duda et al.28	 EPC	












Future	 studies	 should	 concentrate	 on	 analyzing	 the	 diagnostic	
value	of	CEC	counts	in	a	broader	range	of	cardiovascular	diseases.	
Determination	of	CEC	counts	during	and	after	therapy	will	be	cru-
cial	 to	 understand	 their	 potential	 use	 for	 diagnosis	 and	 therapy	
monitoring.47,48
Elevated	CEC	counts	may	even	serve	as	early	diagnostic	tool	for	
endothelial	 damage	 in	 pre-	symptomatic	 disease.	 As	 CECs	 are	 the	
more	 sensitive	 biomarker	 for	 endothelial	 damage,	 further	 efforts	
should	concentrate	on	improving	the	sensitivity	of	CEC	detection	in	
order	to	increase	diagnostic	sensitivity.
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